Merus N.V. (MRUS)

NASDAQ: MRUS · IEX Real-Time Price · USD
15.83
-0.24 (-1.49%)
Feb 3, 2023, 4:00 PM EST - Market closed
-1.49%
Market Cap 732.97M
Revenue (ttm) 45.63M
Net Income (ttm) -63.64M
Shares Out 46.30M
EPS (ttm) -1.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 154,793
Open 16.10
Previous Close 16.07
Day's Range 15.72 - 16.23
52-Week Range 12.03 - 30.81
Beta 0.82
Analysts Buy
Price Target 36.92 (+133.23%)
Earnings Date Feb 27, 2023

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145,... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 19, 2016
Employees 93
Stock Exchange NASDAQ
Ticker Symbol MRUS
Full Company Profile

Financial Performance

In 2021, Merus's revenue was $49.11 million, an increase of 64.00% compared to the previous year's $29.94 million. Losses were -$66.82 million, -21.86% less than in 2020.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for MRUS stock is "Buy." The 12-month stock price forecast is $36.92, which is an increase of 133.23% from the latest price.

Price Target
$36.92
(133.23% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Merus to Participate in Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodie...

4 days ago - GlobeNewsWire

CORRECTING and REPLACING --Merus Provides 2023 Outlook

In a release issued January 8, 2023 by Merus N.V. (Nasdaq:MRUS) with the same headline, an error was made stating Merus plans to provide a regulatory path and program update on petosemtamab in the sec...

3 weeks ago - GlobeNewsWire

Merus Provides 2023 Outlook

- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy

1 month ago - GlobeNewsWire

Merus N.V. (MRUS) Reports Q3 Loss, Misses Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 11.67% and 38.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Merus Announces Financial Results for the Third Quarter and Provides Business Update

– Clinical update of MCLA-129 presented at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics – Zenocutuzumab (Zeno) Regulatory update: FDA recommends additional enro...

3 months ago - GlobeNewsWire

Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

- MCLA-129 observed to be well tolerated with a favorable safety profile

3 months ago - GlobeNewsWire

Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

– MCLA-129 observed to be well tolerated with preliminary evidence of anti-tumor activity during dose escalation phase

4 months ago - GlobeNewsWire

Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innov...

5 months ago - GlobeNewsWire

Merus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodi...

5 months ago - GlobeNewsWire

Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 80% and 20.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Merus Announces Financial Results for the Second Quarter and Provides Business Update

- Clinical update of zenocutuzumab (Zeno) presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

6 months ago - GlobeNewsWire

Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 05, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innova...

8 months ago - GlobeNewsWire

Does Merus N.V. (MRUS) Have the Potential to Rally 113% as Wall Street Analysts Expect?

The mean of analysts' price targets for Merus N.V. (MRUS) points to an 113.4% upside in the stock.

8 months ago - Zacks Investment Research

Merus to Participate in a Fireside Chat at the Jefferies Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodie...

8 months ago - GlobeNewsWire

Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

- Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types

9 months ago - GlobeNewsWire

Down 32.1% in 4 Weeks, Here's Why Merus N.V. (MRUS) Looks Ripe for a Turnaround

Merus N.V. (MRUS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin...

9 months ago - Zacks Investment Research

Merus N.V. (MRUS) Loses 30.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Merus N.V. (MRUS) as it is technically in oversold territory now.

9 months ago - Zacks Investment Research

Merus to Present at the H.C. Wainwright Global Investment Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies...

9 months ago - GlobeNewsWire

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) delivered earnings and revenue surprises of 34.85% and 36.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update

- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Company to host investor call on Sunday, June 5 at 6:00 p.m. ...

9 months ago - GlobeNewsWire

Zenocutuzumab Clinical Abstract Selected for Oral Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innov...

10 months ago - GlobeNewsWire

Merus Announces Publication in Nature Cancer on Petosemtamab's (MCLA-158) Unique Mechanism of Action

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innov...

10 months ago - GlobeNewsWire

7 Top-Rated Biotech Stocks to Buy for Q2

In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill.

10 months ago - InvestorPlace

Merus Presents Preclinical Data on MCLA-129 at the American Association for Cancer Research Annual Meeting 2022

– MCLA-129 promotes Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) of non-small cell lung cancer (NSCLC) cells– MCLA-129 significantly in...

10 months ago - GlobeNewsWire

Merus to Participate in a Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodi...

10 months ago - GlobeNewsWire